Janus Henderson Group PLC Purchases 140,308 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR

Janus Henderson Group PLC boosted its position in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 30.9% in the first quarter, Holdings Channel reports. The fund owned 594,712 shares of the company’s stock after acquiring an additional 140,308 shares during the period. Janus Henderson Group PLC’s holdings in Immunocore were worth $17,919,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. Leonteq Securities AG acquired a new stake in shares of Immunocore in the fourth quarter valued at about $30,000. Harbour Investments Inc. boosted its stake in Immunocore by 60.2% during the 4th quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock valued at $36,000 after purchasing an additional 388 shares during the period. Rockefeller Capital Management L.P. acquired a new stake in Immunocore in the 4th quarter valued at approximately $47,000. Arax Advisory Partners grew its holdings in Immunocore by 302.9% in the 4th quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock valued at $48,000 after buying an additional 1,042 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in Immunocore by 37.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock worth $74,000 after buying an additional 572 shares during the period. 84.50% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

IMCR has been the subject of several research reports. HC Wainwright reissued a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a research report on Monday, April 20th. Mizuho increased their price target on shares of Immunocore from $34.00 to $35.00 and gave the company a “neutral” rating in a report on Monday. Zacks Research downgraded shares of Immunocore from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Wall Street Zen cut shares of Immunocore from a “buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Immunocore in a research report on Monday, July 13th. Five research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $56.29.

Immunocore Stock Down 4.1%

IMCR opened at $32.43 on Tuesday. Immunocore Holdings PLC Sponsored ADR has a fifty-two week low of $27.56 and a fifty-two week high of $40.71. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.18 and a quick ratio of 4.15. The firm’s fifty day moving average price is $31.26 and its two-hundred day moving average price is $31.32. The company has a market capitalization of $1.65 billion, a P/E ratio of -58.96 and a beta of 0.74.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.51. Immunocore had a negative return on equity of 7.07% and a negative net margin of 6.68%.The company had revenue of $106.68 million during the quarter, compared to analysts’ expectations of $145.20 million. During the same period last year, the business earned $0.10 earnings per share. The business’s revenue was up 13.6% on a year-over-year basis. On average, analysts anticipate that Immunocore Holdings PLC Sponsored ADR will post 0.06 EPS for the current year.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.